127 related articles for article (PubMed ID: 35940587)
1. Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non-valvular atrial fibrillation.
Zhang D; Qin W; Du W; Wang X; Chen W; Li P
Biopharm Drug Dispos; 2022 Aug; 43(4):163-171. PubMed ID: 35940587
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study.
Zhang F; Chen X; Wu T; Huang N; Li L; Yuan D; Xiang J; Wang N; Chen W; Zhang J
Clin Pharmacokinet; 2022 Jun; 61(6):881-893. PubMed ID: 35316848
[TBL] [Abstract][Full Text] [Related]
3. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation.
Wu T; Wu S; Li L; Xiang J; Wang N; Chen W; Zhang J
Hum Genomics; 2023 Jul; 17(1):59. PubMed ID: 37420302
[TBL] [Abstract][Full Text] [Related]
4. Impact of gene polymorphisms in drug-metabolizing enzymes and transporters on trough concentrations of rivaroxaban in patients with atrial fibrillation.
Nakagawa J; Kinjo T; Iizuka M; Ueno K; Tomita H; Niioka T
Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):297-304. PubMed ID: 32920985
[TBL] [Abstract][Full Text] [Related]
5. Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
Sychev DA; Sokolov AV; Reshetko OV; Fisenko VP; Sychev IN; Grishina EA; Bochkov PO; Shevchenko RV; Abdullaev SP; Denisenko NP; Ivashchenko DV; Sozaeva ZA; Kachanova AA
Pharmacogenet Genomics; 2022 Dec; 32(9):301-307. PubMed ID: 36256705
[TBL] [Abstract][Full Text] [Related]
6. The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation.
Zhu Z; Qian C; Su C; Tao H; Mao J; Guo Z; Zhu X; Pan J
BMC Cardiovasc Disord; 2022 Nov; 22(1):481. PubMed ID: 36368930
[TBL] [Abstract][Full Text] [Related]
7. The Influence of ABCB1 (rs1045642 and rs4148738) Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation.
Sychev D; Ostroumova O; Cherniaeva M; Shakhgildian N; Mirzaev K; Abdullaev S; Denisenko N; Sozaeva Z; Kachanova A; Gorbatenkova S; Shastina V
High Blood Press Cardiovasc Prev; 2022 Sep; 29(5):469-480. PubMed ID: 35960493
[TBL] [Abstract][Full Text] [Related]
8. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines.
Sennesael AL; Panin N; Vancraeynest C; Pochet L; Spinewine A; Haufroid V; Elens L
Sci Rep; 2018 Jul; 8(1):10514. PubMed ID: 30002384
[TBL] [Abstract][Full Text] [Related]
9. The Distribution of the Genotypes of
Abdrakhmanov A; Akilzhanova A; Shaimerdinova A; Zhalbinova M; Tuyakova G; Abildinova S; Albayev R; Ainabekova B; Chinybayeva A; Suleimen Z; Bekbossynova M
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372371
[TBL] [Abstract][Full Text] [Related]
10. Common P-glycoprotein (
Slišković AM; Palić J; Božina T; Ganoci L; Vrkić Kirhmajer M; Trkulja V; Bulum J; Šimičević L
Biochem Med (Zagreb); 2024 Jun; 34(2):020703. PubMed ID: 38665866
[TBL] [Abstract][Full Text] [Related]
11. Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of
Song H; Bai W; Sun X; Qiu B; Guo N; Guo C; Hu Y; Dong Z
Xenobiotica; 2021 Dec; 51(12):1463-1469. PubMed ID: 34979850
[TBL] [Abstract][Full Text] [Related]
12. Influence of
Wang Y; Chen M; Chen H; Wang F
Front Pharmacol; 2021; 12():639854. PubMed ID: 33935730
[No Abstract] [Full Text] [Related]
13. Population Pharmacokinetics and Hemorrhagic Risk Analysis of Rivaroxaban in Elderly Chinese Patients With Nonvalvular Atrial Fibrillation.
Zhang D; Chen W; Qin W; Du W; Wang X; Zuo X; Li P
J Clin Pharmacol; 2023 Jan; 63(1):66-76. PubMed ID: 36029108
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study.
Xiang Q; Wang Z; Mu G; Xie Q; Liu Z; Zhou S; Zhang H; Wang Z; Jiang J; Hu K; Zhang Y; Zhao Z; Yuan D; Guo L; Wu T; Zhang J; Wang N; Xiang J; Gu Z; Sun J; Cui Y
Clin Transl Med; 2023 May; 13(5):e1263. PubMed ID: 37203300
[TBL] [Abstract][Full Text] [Related]
15. Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy.
Ma Y; Song Z; Li X; Jiang D; Zhao R; Yi Z
Clin Pharmacokinet; 2024 Mar; 63(3):279-291. PubMed ID: 38460105
[TBL] [Abstract][Full Text] [Related]
16. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.
Lähteenmäki J; Vuorinen AL; Pajula J; Harno K; Lehto M; Niemi M; van Gils M
Clin Pharmacol Ther; 2021 Sep; 110(3):768-776. PubMed ID: 34043814
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery.
Sychev D; Minnigulov R; Bochkov P; Ryzhikova K; Yudina I; Lychagin A; Morozova T
High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):413-420. PubMed ID: 31617197
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]